Zimbos Now Buying ARVs In Zambia

PEOPLE Living With HIV have resorted to buying Antiretroviral drugs from neighboring Zambia amidst fears of developing side effects from the expired stocks currently being dispensed in some health institutions. By Kudakwashe Pembere & Michael Gwarisa This is despite the assurance from the Medicines Control Authority of Zimbabwe (MCAZ) that the medicines have been tested and certified safe for consumption by people living with HIV. Speaking to HealthTimes on the sidelines of a march against ARV stock-outs,  Gumisai Bonzo a women living with HIV said they have organised groups to…

Share
Read More

Parliament Petitioned Over ARV Shortages

PEOPLE Living With HIV (PLHIV) have handed over a petition to the Parliament of Zimbabwe in a bid to push government to urgently allocate financial resources to arrest the prevailing drug shortage before the situation goes out of hand. By Michael Gwarisa The development comes at the back of indications that the National Aids Council (NAC) is sitting on a cash pile of RTGS$20 million which they are failing to convert to United States (US) dollars needed to procure drugs from source markets. In an interview on the side-lines of…

Share
Read More

DTG Won’t Be Forced On Citizens- Ministry

PEOPLE Living With HIV (PLHIV) and on Antiretroviral Therapy (ART) still have the option to continue taking other ART options apart from Dolutogravir (DTG) based regimens  since the process is not compulsory, a ministry of health and child care (MoHCC) official has said. By Michael Gwarisa in Gweru Zimbabwe commenced its transition process from Tenovir/Lamuvidene/Efavirens to Dolutegravir (DTG) in May 2019, and the transition procedure will be completed by February 2020. Briefing a women living with HIV, Sexual Reproductive Health and Rights (SRHR) workshop organised by PAPWC/ZIM,  ZWLHNF and UNAIDS,…

Share
Read More

Demystifying Dolutegravir based antiretroviral drug regimens

ZIMBABWE recently joined other nations to adopt the new HIV treatment regimens that contain Dolutegravir (DTG).  The complete transition process for Zimbabwe however, will not take less than 10 months to be fully implemented considering that the country has over a million people on first line HIV medicines. By Michael Gwarisa and Dr. Simbarashe Mabaya Countries  adopt normative guidance by the World Health Organization (WHO) which is based on rigorous review and analysis of scientific evidence. Based on this review WHO develops recommendations which make up the next guidelines. Countries…

Share
Read More

Zim Commences DTG Drug Transition

DEPUTY Director HIV/AIDS and STIs in the ministry of health and child care (MoHCC), Dr Tsitsi Apollo says the country has already commenced its transition process from Tenovir/Lamuvidene/Efavirens to Dolutegravir (DTG), a first line regimen of Antiretroviral Therapy (ART) which has less side effected and a rapid viral suppression. By Michael Gwarisa The whole transition process will be completed come February 2020 and in the process, drugs such as Navirapine (NVP) will be phased out with indications on the ground confirming that healthcare providers have already been advised to limit…

Share
Read More

Zim Defers HIV Drug Roll Out…Drug Deforms Unborn Babies

THE Ministry of Health and Child Care (MoHCC) has deffered roll out of the HIV  Dolutegravir (DTG) drug  following indications that it causes complications in women of child bearing age and adolescent girls, which might lead to deformities in unborn babies born to HIV positive mothers taking the drug at the time of conception. HealthTimes Reporter Zimbabwe intended to scale up Dolutegravir as a first choice ARV to all people living with HIV in the country next year. The drug is currently being used to manage HIV in people who fail…

Share
Read More